Forever young: the business of longevity drugs
From The Intelligence from The Economist · · 23 min
This plays from the publisher's own server. We do not host a copy.
Description
The success of GLP-1s has prompted biotechs to approach the challenge differently. After years of false starts and disappointing results, longevity drugs (https://www.economist.com/business/2026/11/02/the-quest-for-immortality-has-become-serious-business?utm_campaign=a.io&utm_medium=audio.podcast.np&utm_source=theintelligence&utm_content=discovery.content.anonymous.tr_shownotes_na-na_article&utm_term=sa.listeners) could be on the horizon. Do immigrants from some countries commit more sex crimes (https://www.economist.com/britain/2026/10/25/do-immigrants-from-some-countries-commit-more-sex-crimes?utm_campaign=a.io&utm_medium=audio.podcast.np&utm_source=theintelligence&utm_content=discovery.content.anonymous.tr_shownotes_na-na_article&utm_term=sa.listeners)? And the big business of miniatures (https://www.economist.com/culture/2026/10/13/whats-behind-the-big-interest-in-miniatures?utm_campaign=a.io&utm_medium=audio.podcast.np&utm_source=theintelligence&utm_content=discovery.content.anonymous.tr_shownotes_na-na_article&utm_term=sa.listeners).
Guests and host:
- Shailesh Chitnis, global business writer
- James Fransham, data correspondent
- Sascha Lowdermilk, culture intern
- Ọrẹ Ogunbiyi, co-host of “The Intelligence”
Topics covered:
- Longevity drugs, biotechnology, ageing
- Immigration, sex crime, Britain
- Miniatures, 3D printing, hobbies
Listen to what matters most, from global politics and business to science and technology—subscribe to The Economist (https://subscribenow.economist.com/podcasts-plus).
Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.
Back to The Intelligence from The Economist · Report a problem